Sarecycline - An Overview

Drug Overview:

Sarecycline is recommended for managing some forms of acne in adults and children over nine years of age. As a member of the Tetracycline antibiotic group, the drug works for acne by killing bacteria that cause pore infections and preventing excess sebum production. That said, drugs such as Sarecycline will not help treat colds or flu. The misuse of medications, mainly through inappropriate self-medication, can contribute to the development of drug-resistant infections. It was approved by the FDA for oral administration in 2018.

For Patients:

What Are the Clinical Indications For Sarecycline?

Sarecycline is an oral drug used for the treatment of acne vulgaris in adults and children over nine years of age.

What Is the Dosage of Sarecycline?

The tablet is available in three different dosages: 60 milligrams (mg), 100 mg, and 150 mg, which are given to children depending on their weight.

What Are the Things to Inform the Doctor Before Taking the Drug?

They should also inform the doctors about the below-mentioned conditions:

• Pregnancy.

• Heart disease.

• Kidney diseases.

• Stroke.

• Cancer.

• Breastfeeding.

• Diabetes.

How Is Sarecycline Administered?

Sarecycline is an orally administered antibiotic in tablet form and is usually taken once daily, always with or without food. It is advisable to take a full glass of water with each dose and take this medicine simultaneously every day. Patients must take their medicines exactly as prescribed and in the correct amounts, as there is a risk of self-interpretation of simplifications. It is necessary to use Sarecycline as directed and not change the medicine dosage or the frequency of taking it. If treatment with Sarecycline is stopped too early or if doses are missed, the infection may not be fully treated, increasing the risk of antibiotic-resistant organisms emerging.

What Are the Side Effects of Sarecycline?

• Nausea.

• Vaginal itching or discharge.

• Severe headache.

• Blurred vision.

• Watery or bloody stools.

• Stomach cramps.

• Fever.

Missed Dose:

If a dose of Sarecycline is missed, it should be taken as soon as possible to maintain a regular dosage schedule. However, when it almost concerns the next dose, the missed dose should be ignored, and the process should continue with the proper schedule. It is preferable not to take a double dose as compensation for a missed one.

Overdose:

Administration of the medicine in overdose should be stopped altogether, and managing the symptoms or providing any kind of supportive treatment should be initiated. As for the drug itself, hemodialysis does not shorten the serum half-life. Thus the risk of engaging in the therapy of overdose is redundant.

Storage:

Store at a temperature between 20 to 25 degrees Celsius.

For Doctors:

Indication:

The Sarecycline tablet is prescribed for treating inflammatory lesions of non-nodular moderate to severe acne vulgaris in individuals nine and older.

Dose:

The recommended dosage of Sarecycline is once daily, with or without food, as follows:

• 60 mg for patients weighing 33 to 54 kilograms (kg).

• 100 mg for patients weighing 55 to 84 kg.

• 150 mg for patients weighing 85 to 136 kg.

Dosing Considerations:

• Sarecycline should be stopped if the patient does not improve adequately by twelve weeks of treatment.

• Sarecycline is to be administered once daily without regard to the meals.

• If an aseptic postural esophagus inflammation is to be avoided, ensure sufficient amounts of fluids are taken when the patient consumes Sarecycline.

Pharmacological Aspects of Sarecycline

Mechanism of Action

Belonging to this class of antibiotics, Sarecycline can inhibit protein synthesis in bacteria, a classic feature of tetracycline antibiotics. This inhibition occurs through a specific binding to the ribosome, which plays a fundamental role in the translation process.

• Binding to the Ribosome: Due to its high specificity, Sarecycline penetrates the 30 ribosomal subunits of bacterial ribosomes. The ribosome is a cellular machinery that carries out the translation of mRNA into protein.

• Blocking tRNA Binding: By binding to the 30S subunit, Sarecycline blocks the interactions between aminoacyl-tRNA and the A site of the ribosome. This site is where tRNA brings amino acids and incorporates them into the elongating peptide chain for protein synthesis.

• Inhibition of Protein Elongation: Sarecycline's attachment inhibits the further addition of various amino acids to the peptide chains. This action decrements the elongation stage of protein synthesis, an important process for bacteria to thrive and multiply.

• Bacterial Growth Inhibition: By halting protein synthesis, the bacteria cannot produce the proteins needed for reproduction, growth, and other vital functions. This lowers the number of bacteria and thus stops the further development of bacterial infections.

• Impact on Acne Treatment: Regarding acne, the mechanism of action of Sarecycline is directed against Propionibacterium acnes or Cutibacterium acnes, which is involved in acne inflammation. Since Sarecycline decreases the bacterial load and inflammation in the pores, it reduces the extent of the acne lesions and makes the skin generally healthy.

Pharmacodynamics

• Antimicrobial Activity: A Saracycline component that works on the specific bacterium causing acne, Cutibacterium acnes has a potent range of activity against various acne-associated bacteria. It has been conclusively established that this bacterium plays an essential role in developing acne through excessive growth in the sebaceous glands and the inflammatory processes. Because Sarecycline inhibits protein synthesis, it helps minimize the number of bacteria-contaminated in the skin. This reduction in bacterial populations is beneficial because it reduces infection and the chances of new acne breakouts.

• Anti-Inflammatory Properties: Aside from the robust antimicrobial effects of Sarecycline, it also has mild anti-inflammatory effects. This is accomplished by inhibiting the activities of pro-inflammatory mediators and cytokines, thus reducing the inflammatory response in the skin. This is necessary to help soothe the redness, swelling, and pain that usually develops in areas that have acne lesions. Reducing inflammation will also improve the lesions associated with acne, ensuring no further advancing of the disease from mild to more severe forms of acne. Thus, inflammation is established as the primary cause of the formation of pustules, papules, and nodules, and Sarecycline addresses this.

• Skin Penetration and Distribution: Sarecycline's formulation is designed to penetrate the skin efficiently, reaching the subcutaneous and sebaceous glands where acne-causing bacteria reside. The manner and extent to which the drug penetrates the skin ensures that adequate amounts of the drug are delivered to the region of the lesions, increasing its therapeutic benefits. This localized mechanism of action has the advantage of improved control of bacterial growth and the following inflammatory process.

• Overall Effectiveness: Sarecycline's synergistic antimicrobial and anti-inflammatory properties render it a holistic solution for treating acne. Since It is effective against inflammatory responses and bacterial causes, it offers a twofold approach to treating acne and skin care.

Pharmacokinetics

• Absorption: After oral dosing, Sarecycline is well absorbed from the gastrointestinal tract. This high level of absorption ensures that therapeutic concentrations of the drug are achieved in the body. Food present in the stomach does not significantly influence the absorption of Sarecycline. This means that the drug can be consumed with or without food and still be effective, or its absorption rate would not be significantly altered.

• Distribution: Once the drug is absorbed, it circulates throughout the body in the blood, where Sarecycline is distributed. This distribution encompasses reach and various tissues and organs; hence, the drug can reach sites with acne lesions. Sarecycline can also permeate the skin, including the sebaceous glands and pores, which are the target sites in the acne treatment. The drug's tendency to permeate into the skin and get lodged in its layers enhances its anti-acne effects. The drug is known to be associated with plasma proteins; this might alter its distribution and availability at the site of action.

• Metabolism: Sarecycline's metabolism appears to be more limited, with the liver as the organ of drug metabolism. This means that very little of the drug changes its chemical structure before it is eliminated from the body. Because of the lack of metabolism, Sarecycline has a relatively low chance of causing side effects from concomitant use compared to other medications that involve the liver metabolizing enzymes or metabolic processes.

• Excretion: The more significant part of Sarecycline is eliminated in urine intact, without the kidneys metabolizing it. This method of elimination removes the drug from the body after the desired therapeutic effects are achieved. Sarecycline can comfortably be given once a day due to the flow of the serum half-life. The half-life is the length of time for the concentration of the drug in the blood to be halved; therefore, a reasonable half-life will mean that the drug is effective in the body for the whole day, even after a single dose.

Clinical Studies And Efficacy:

• The rates of adverse reactions reported in clinical studies are often influenced by the situations surrounding the studies, implying that these rates may be hard to compare with those obtained from other drugs or even in industry practice.

• In three controlled clinical trials, 1064 subjects with moderate to severe acne vulgaris were treated with Sarecycline for 12 weeks, whereas 1069 subjects received a placebo for 12 weeks.

• Nausea was the only adverse reaction reported in one percent, occurring in 3.1 percent of Sarecycline-treated patients.

• Other adverse reactions that are rare in female subjects treated with Sarecycline were vulvovaginal mycotic infection in 0.8 percent and vulvovaginal candidiasis in 0.6 percent of patients.

What Are the Contraindications of Sarecycline?

Sarecycline is contraindicated for individuals who have hypersensitivity to any tetracycline antibiotics.

Warnings and Precautions:

• Teratogenic Effects: Sarecycline, as is the case with all tetracyclines, will be harmful to the fetus if exposed to a pregnant woman. Where Sarecycline is utilized during pregnancy or where a patient wishes to consider conception while using Sarecycline, the possible risk to the patient’s hoary dreams should be articulated, and the drug should be stopped. It is known that tetracyclines taken during periods of tooth formation (the 2nd and 3rd trimesters of pregnancy, infancy, and childhood lower than eight years of age) can result in permanent tooth staining (yellow-grey or brown). Discoloration of this adverse effect is mainly witnessed in individuals in the long term, with the same occurrences also seen with repeated short-duration treatment courses. There have also been cases of enamel hypoplasia. Tetracyclines are known to bind to calcium in all bones and bone-making tissues, and there have been cases of poor fibula growth in preterm babies treated with oral tetracycline. This reaction was reversible after withdrawal of the medication. Animal tests show that tetracyclines penetrate the fetal membranes, are found in the fetal tissues, and can affect the degree of fetal bone growth. A dose of Sarecycline administered to an animal during pregnancy has been associated with embryotoxicity during pregnancy, extending to maternal toxicity.

• Clostridium Difficile Associated Diarrhea (Antibiotic-Associated Colitis): Antimicrobial-Induced Diarrhea: Antimicrobial Associated Diarrhea (CDAD) is a term linked to every group of antibacterials that has been documented and goes from mild forms of diarrhea too, in its more virulent form, even death provoking colitis. Antibiotics can also kill a person’s normal colonic bacteria, allowing for the excessive growth of C. difficile. The development of C. difficile-associated diarrhea depends on toxins A and B. Hyper toxin-producing strains also cause severe conditions, hence the need for a colectomy procedure. CDAD must be considered whenever a patient develops diarrhea following the intake of antibiotic strategies, as the study may last for up to two months after administering an antibiotic.

• Central Nervous System Effects: Most central nervous system effects, such as light-headedness, dizziness, or vertigo, are noted among patients who are placed on tetracycline drugs. Medication of this type can alter the central nervous system, and the elderly should be careful while operating machines or driving. These effects may be experienced throughout treatment or even after stopping the medication.

• Intracranial Hypertension: There is evidence linking intracranial hypertension and the use of tetracycline in both adults and children. Signs may include headache, visual obscurations, and papilledema. Although typical signs and symptoms often return after the drug is discontinued, the possibility of either total or near-total visual loss remains. This population is at higher risk than male counterparts and overweight women of childbearing age. Visual assessment needs to be done in patients before tetracyclines. Simultaneous treatment with isotretinoin and Sarecycline should be avoided due to the risk of developing intracranial hypertension with isotretinoin. Patients experiencing any visual problems during the course of the treatment must be screened for papilledema.

• Photosensitivity: An exaggerated response to extreme heat from sunburn has been noted with the use of tetracyclines, a phenomenon called photosensitivity. Saracycline should be cautiously applied to the skin since it may cause sunlight allergy. Where such activity is unavoidable, physical protective devices and clothes should be employed and more sun-safe measures should be availed on the advice of the physician.

• Development of Drug-Resistant Bacteria: Conditions conducive to the emergence of bacterial resistance to tetracyclines are likely to be triggered by the medication of Sarecycline. In order to reduce the chances of facing such a problem, the usage of Sarecycline should be restricted to the indicated conditions only.

• Potential for Microbial Overgrowth: As it is similar to other antibiotics, there is also some potential with Sarecycline to have non-susceptible organisms including fungi. In case a superinfection is present discontinuation of the treatment is a must followed by an appropriate treatment plan.

Specific Considerations

• Pregnancy: Like other drugs of the Tetracycline class, Sarecycline too may have an adverse effect on the fetus and cause possible damage and/or permanent discoloration of developing teeth or reversible restriction of bone development when used in the course of pregnancy. The available human data is however inadequate to quantify any specific risk for birth defects or miscarriage. Use of tetracyclines in pregnancy should be avoided since they are secreted into the placental tissues, and hence Sarecycline can be passed onto the growing fetus from the mother.

• Lactation: The tetracycline group of antibiotics is excreted in human milk. Because of the potential for serious toxicity of tetracycline-appended antibiotic agents that may negatively affect the bone and tooth structure of the breastfed child, the use of Sarecycline during lactation is not recommended.

• Females and Males of Reproductive Potential: A fertility study carried out in rats revealed that the oral administration of Sarecycline to male rats decreases the number and quality of sperm produced in the male rats.

• Pediatric Use: The safety and efficacy of the drug have been found for patients nine years of age and older for the purpose of treatment of moderate to severe inflammatory lesions of non-nodular acne vulgaris. However, the safety and efficacy have not been determined for the age group of eight years and younger. The use of antibiotics from the Tetracycline class is contraindicated in children less than eight years of age due to the risk of tooth stains.

• Geriatric Use: The clinical studies carried out on Sarecycline lacked a proper number of participants aged 65 years and over, hence it is not known how they might respond to treatment compared to younger patients.